Oral direct‐acting antiviral therapy to prevent reinfection of the liver graft after liver transplantation for hepatitis C virus–related cirrhosis
Paul Y. Kwo, A. Joseph Tector – 15 June 2013
Calcineurin Inhibitor–Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare‐the‐Nephron Trial
Lewis Teperman, Dilip Moonka, Anthony Sebastian, Linda Sher, Paul Marotta, Christopher Marsh, Baburao Koneru, John Goss, Dennis Preston, John P. Roberts, Spare‐the‐Nephron Trial Liver Transplantation Study Group – 15 June 2013 – Mycophenolate mofetil (MMF) and sirolimus (SRL) have been used for calcineurin inhibitor (CNI) minimization to reduce nephrotoxicity following liver transplantation.
Improved Waiting‐List Outcomes in Argentina After the Adoption of a Model for End‐Stage Liver Disease–Based Liver Allocation Policy
Nora Gabriela Cejas, Federico G. Villamil, Javier C. Lendoire, Viviana Tagliafichi, Arturo Lopez, Daniela Hansen Krogh, Carlos A. Soratti, Liliana Bisigniano – 15 June 2013 – In July 2005, Argentina became the first country after the United States to introduce the Model for End‐Stage Liver Disease (MELD) for organ allocation. In this study, we investigated waiting‐list (WL) outcomes (n = 3272) and post–liver transplantation (LT) survival in 2 consecutive periods of 5 years before and after the implementation of a MELD‐based allocation policy.
Reply
Wim Laleman, Geert Maleux, Juan Cordoba, Frederik Nevens – 14 June 2013
Liver transplantation normalizes serum hepcidin level and cures iron metabolism alterations in HFE hemochromatosis
Edouard Bardou‐Jacquet, Julie Philip, Richard Lorho, Martine Ropert, Marianne Latournerie, Pauline Houssel‐Debry, Dominique Guyader, Olivier Loréal, Karim Boudjema, Pierre Brissot – 14 June 2013 – Defects in human hemochromatosis protein (HFE) cause iron overload due to reduced hepatic hepcidin secretion. Liver transplantation (LT) is a key treatment for potential complications from HFE‐related hereditary hemochromatosis (HH). This study evaluated hepcidin secretion and iron burden after LT to elucidate HH pathophysiology.
Embolization of spontaneous portosystemic shunts for management of severe persistent hepatic encephalopathy
Siddharth Singh, Patrick S. Kamath, James C. Andrews, Michael D. Leise – 14 June 2013
Reply
Sarah Larney, Nickolas D. Zaller, Louisa Degenhardt – 14 June 2013
Hepatitis C virus transmission risk in incarcerated or detained populations
Ethan K. Gough, Mirjam‐Colette Kempf, Eric Chamot – 14 June 2013
Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma
Laurent Sulpice, Michel Rayar, Mireille Desille, Bruno Turlin, Alain Fautrel, Eveline Boucher, Francisco Llamas‐Gutierrez, Bernard Meunier, Karim Boudjema, Bruno Clément, Cédric Coulouarn – 14 June 2013 – Intrahepatic cholangiocarcinoma (ICC) is the second most common type of primary cancer in the liver. ICC is an aggressive cancer with poor prognosis and limited therapeutic strategies. The identification of new drug targets and prognostic biomarkers is an important clinical challenge for ICC. The presence of an abundant stroma is a histological hallmark of ICC.
Induction of autophagy, a promising approach for treating liver injury
Wen‐Xing Ding – 14 June 2013